Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yaochang Yuan

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Plos Pathogens|February 27, 2020
Two waves of pro-inflammatory factors are released during the influenza A virus (IAV)-driven pulmonary immunopathogenesisJunsong Zhang, Jun Liu, Yaochang Yuan, et al.
Frontiers in Immunology|September 13, 2021
Brd4 Regulates the Homeostasis of CD8<sup>+</sup> T-Lymphocytes and Their Proliferation in Response to Antigen StimulationZhilin Peng, Yiwen Zhang, Xiancai Ma, et al.
NPJ Vaccines|May 18, 2025
An RBD-Fc mucosal vaccine provides variant-proof protection against SARS-CoV-2 in mice and hamstersYanjun Zhang, Yan Wu, Meng-Qian Zhang, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 22, 2021
The ORF8 protein of SARS-CoV-2 mediates immune evasion through down-regulating MHC-ΙYiwen Zhang, Yingshi Chen, Yuzhuang Li, et al.
Cell Reports|January 6, 2022
A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2Yaochang Yuan, Xiantao Zhang, Ran Chen, et al.
Immunity|December 4, 2020
Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune ResponsesXiancai Ma, Fan Zou, Fei Yu, et al.
Frontiers in Microbiology|May 16, 2022
Glycopeptide Antibiotic Teicoplanin Inhibits Cell Entry of SARS-CoV-2 by Suppressing the Proteolytic Activity of Cathepsin LFei Yu, Ting Pan, Feng Huang, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|February 10, 2022
Development of Receptor Binding Domain (RBD)-Conjugated Nanoparticle Vaccines with Broad Neutralization against SARS-CoV-2 Delta and Other VariantsRan Chen, Xiantao Zhang, Yaochang Yuan, et al.
Nature Immunology|March 7, 2024
The receptor binding domain of SARS-CoV-2 Omicron subvariants targets Siglec-9 to decrease its immunogenicity by preventing macrophage phagocytosisXin He, Xiantao Zhang, Bolin Wu, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Plos Pathogens|February 27, 2020
Two waves of pro-inflammatory factors are released during the influenza A virus (IAV)-driven pulmonary immunopathogenesisJunsong Zhang, Jun Liu, Yaochang Yuan, et al.
Frontiers in Immunology|September 13, 2021
Brd4 Regulates the Homeostasis of CD8<sup>+</sup> T-Lymphocytes and Their Proliferation in Response to Antigen StimulationZhilin Peng, Yiwen Zhang, Xiancai Ma, et al.
NPJ Vaccines|May 18, 2025
An RBD-Fc mucosal vaccine provides variant-proof protection against SARS-CoV-2 in mice and hamstersYanjun Zhang, Yan Wu, Meng-Qian Zhang, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 22, 2021
The ORF8 protein of SARS-CoV-2 mediates immune evasion through down-regulating MHC-ΙYiwen Zhang, Yingshi Chen, Yuzhuang Li, et al.
Cell Reports|January 6, 2022
A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2Yaochang Yuan, Xiantao Zhang, Ran Chen, et al.
Immunity|December 4, 2020
Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune ResponsesXiancai Ma, Fan Zou, Fei Yu, et al.
Frontiers in Microbiology|May 16, 2022
Glycopeptide Antibiotic Teicoplanin Inhibits Cell Entry of SARS-CoV-2 by Suppressing the Proteolytic Activity of Cathepsin LFei Yu, Ting Pan, Feng Huang, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|February 10, 2022
Development of Receptor Binding Domain (RBD)-Conjugated Nanoparticle Vaccines with Broad Neutralization against SARS-CoV-2 Delta and Other VariantsRan Chen, Xiantao Zhang, Yaochang Yuan, et al.
Nature Immunology|March 7, 2024
The receptor binding domain of SARS-CoV-2 Omicron subvariants targets Siglec-9 to decrease its immunogenicity by preventing macrophage phagocytosisXin He, Xiantao Zhang, Bolin Wu, et al.
Pageof 2